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1. INTRODUCTION {#brb3791-sec-0005}
===============

Mild traumatic brain injury (mTBI) is a major cause of cognitive impairment, which may be modulated in part by genetic susceptibility. mTBIs constitute 70%--90% of all traumatic brain injuries (TBI) (Cassidy et al., [2004](#brb3791-bib-0015){ref-type="ref"}); it is estimated that 20%--25% of patients experience persistent symptoms and/or cognitive and neuropsychiatric deficits at 6--12 months postinjury (Arciniegas, Anderson, Topkoff, & McAllister, [2005](#brb3791-bib-0005){ref-type="ref"}). A major health system challenge is that individuals with similar injuries will often manifest different symptoms, follow divergent clinical trajectories, and have varied functional outcomes (Ponsford, Draper, & Schönberger, [2008](#brb3791-bib-0071){ref-type="ref"}).

Apolipoprotein E (*APOE*) encodes a lipoprotein (ApoE) released primarily by astrocytes after TBI and is known to promote neuronal survival/outgrowth and exert antioxidant effects in the context of oxidative stress and neuroinflammation (Figure [1](#brb3791-fig-0001){ref-type="fig"}). ApoE is a key regulator of plasma lipid levels produced in abundance in the brain along with ApoE receptors in order to mediate synaptic repair, remodeling, and protection (Blackman, Worley, & Strittmatter, [2005](#brb3791-bib-0011){ref-type="ref"}; Ignatius et al., [1986](#brb3791-bib-0039){ref-type="ref"}; Nathan et al., [1994](#brb3791-bib-0063){ref-type="ref"}). The gene for ApoE is located on chromosome 19 and is highly polymorphic (Friedman et al., [1999](#brb3791-bib-0026){ref-type="ref"}). Differences in the tertiary structure and in the charge distribution of the *APOE* isoforms determine the capacity for cholesterol homeostasis through binding to receptors, to other proteins, and through intracellular trafficking pathways and second messengers (Strittmatter & Bova Hill, [2002](#brb3791-bib-0077){ref-type="ref"}; Saito et al., [2003](#brb3791-bib-0073){ref-type="ref"}). These differences in metabolic regulation may influence the outcome after brain injury. Of its three common alleles (ε*2*, ε*3*, ε*4*), ε*4*---which has reduced antioxidant and biological activity---is a risk factor for neurodegenerative disorders. While *APOE‐*ε*2* and ε*3,* respectively, contain two and one cysteine residues for detoxifying cytotoxic products of lipid peroxidation, *APOE‐*ε*4* expresses two arginine residues and lacks this ability. Hence, *APOE‐*ε*4* is directly associated with mitochondrial toxicity and beta‐amyloid deposition contributing to Alzheimer\'s Disease (AD) in a dose‐dependent manner (ε*4* carrier, 5‐fold; ε*4*/ε*4*: 20‐fold) (Blennow, Mattsson, Schöll, Hansson, & Zetterberg, [2015](#brb3791-bib-0013){ref-type="ref"}; Hauser & Ryan, [2013](#brb3791-bib-0037){ref-type="ref"}).

![Effects of *APOE* on Aβ metabolism and postinjury repair. Neuronal injury upregulates astrocyte secretion of ApoE, which clears lipid cell debris and assists in cholesterol delivery for synaptogenesis. *APOE* is lipidated to form ApoE lipoprotein, and in the extracellular space binds in an isoform‐dependent pattern (*APOE‐*ε*2*,*‐*ε*3 \>  APOE‐*ε*4*) to soluble beta‐amyloid protein (Aβ), a peptidic neurotoxin. *APOE* genotype determines the capacity for Aβ clearance and parenchymal amyloid plaque accumulation. Evidence suggests that relative to *APOE‐*ε*2* and *‐*ε*3*,*APOE‐*ε*4* is preferentially susceptible to proteolytic degradation, thus reducing the capacity to fulfill postinjury needs for membrane repair and synaptogenesis](BRB3-7-e00791-g001){#brb3791-fig-0001}

The *APOE‐*ε*4* allele has been associated with unfavorable outcomes following TBI, including acute clinical deterioration, increased hemorrhage, longer hospital stays, and impaired functional recovery (Chiang, Chang, & Hu, [2003](#brb3791-bib-0017){ref-type="ref"}; Jiang et al., [2007](#brb3791-bib-0042){ref-type="ref"}; Alexander et al., [2007](#brb3791-bib-0002){ref-type="ref"}). This could be due to increased expression of *APOE* in astrocytes following ischemic brain injury and neuronal degeneration (Friedman et al., [1999](#brb3791-bib-0026){ref-type="ref"}), furthered by the association between *APOE‐*ε*4* and increased oxidative stress (Jiang et al., [2006](#brb3791-bib-0043){ref-type="ref"}). In a landmark study of 984 patients by Teasdale et al. in 2005, the *APOE‐*ε*4* allele was associated with decreased functional recovery after controlling for Glasgow Coma Scale (GCS) motor score, pupillary reactivity, and intracranial computed tomography (CT) pathology; ε*4* carriers under age 45 years were conferred up to 25 additional years of aging after suffering TBI (Teasdale, Murray, & Nicoll, [2005](#brb3791-bib-0084){ref-type="ref"}). In moderate and severe TBI patients assessed at least 6 months postinjury, Ariza et al. ([2006](#brb3791-bib-0006){ref-type="ref"}) found that ε*4*‐carriers performed notably worse on tests of frontal lobe function and long‐term memory. In a large Australian cohort stratified by age, the *APOE‐*ε*4* allele was associated with poorer baseline episodic memory and slower reaction time in younger adults with a history of childhood TBI (Eramudugolla et al., [2014](#brb3791-bib-0023){ref-type="ref"}). Similarly, ε*4* carriers may be at more risk for cognitive impairment and chronic traumatic encephalopathy (CTE) (Liberman, Stewart, Wesnes, & Troncoso, [2002](#brb3791-bib-0051){ref-type="ref"}; Müller et al., [2009](#brb3791-bib-0062){ref-type="ref"}; Lenihan & Jordan, [2015](#brb3791-bib-0050){ref-type="ref"}; ). Conversely in children, Moran et al. report that the *APOE‐*ε*4* allele has little impact on neurocognitive measures following TBI, although ε*4*‐carriers were associated with a more negative early response to injury (Moran et al., [2009](#brb3791-bib-0061){ref-type="ref"}), which mirrors the adult literature (Friedman et al., [1999](#brb3791-bib-0026){ref-type="ref"}; Jiang et al., [2006](#brb3791-bib-0043){ref-type="ref"}). Interestingly, pediatric ε*4* carriers sustaining moderate to severe TBI showed poorer adaptive functioning in the context of positive parenting, whereas non‐ε*4‐*carriers displayed worse detriments in the context of less optimal parenting (Treble‐Barna et al., [2016](#brb3791-bib-0085){ref-type="ref"}). These studies further highlight the pleiotropic association between *APOE‐*ε*4* and neurobehavioral outcomes after TBI, and underscore the need to elucidate its relationship with outcome subdomains after different types of TBI.

To date, mild‐to‐moderate TBI studies in the literature have reported mixed associations for verbal memory outcome by *APOE‐*ε*4* status (Chamelian, Reis, & Feinstein, [2004](#brb3791-bib-0016){ref-type="ref"}; Han et al., [2007](#brb3791-bib-0035){ref-type="ref"}; Padgett, Summers, Vickers, McCormack, & Skilbeck, [2016](#brb3791-bib-0068){ref-type="ref"}). Interestingly, Han and colleagues reported improved neuropsychological outcome at 1 month was associated with *APOE‐*ε*4* in the military population (Han et al., [2007](#brb3791-bib-0035){ref-type="ref"}), whereas Crawford et al. ([2002](#brb3791-bib-0018){ref-type="ref"}) reported memory and verbal impairment in military personnel with *APOE‐*ε*4* within 6 months of injury. Using an extensive neuropsychological battery at 3 and 6 weeks postinjury, Liberman et al. ([2002](#brb3791-bib-0051){ref-type="ref"}) reported in adults with mild and moderate TBI that patients with the *APOE‐*ε*4* allele had lower mean scores for nearly all neuropsychological tests and needed more time to complete tasks, although none of the differences were significant. The authors suggested that *APOE* genotype may specifically influence the severity of the acute injury along with delaying recovery. In concussed athletes tested within 6 months of injury, carriers of the ε*4* allele demonstrated greater neurocognitive variability than athletes without an ε*4* allele (Merritt, Rabinowitz, & Arnett, [2017](#brb3791-bib-0058){ref-type="ref"}). However, an Indian cohort of mild‐to‐moderate TBI patients at 6 months showed no clear differences in neuropsychological test performance by *APOE‐*ε*4* status (Pruthi et al., [2010](#brb3791-bib-0072){ref-type="ref"}). Reports of association between ε*4* carriers and postconcussional symptoms months to years postinjury also exist (Sundström et al., [2007](#brb3791-bib-0080){ref-type="ref"}; Merritt & Arnett, [2016](#brb3791-bib-0057){ref-type="ref"}; Pan et al., [2016](#brb3791-bib-0069){ref-type="ref"}). Population characteristics and TBI severity may contribute to the discrepancies in the current literature. Hence, the association of *APOE‐*ε*4* status and subdomains of verbal memory performance following isolated mTBI warrant further study.

For the current analysis, we utilized data from the prospective multicenter Transforming Research and Clinical Knowledge in Traumatic Brain Injury Pilot (TRACK‐TBI Pilot) study (Yue et al., [2013](#brb3791-bib-0091){ref-type="ref"}) to explore associations between *APOE* and components of 6‐month verbal memory postinjury. We demonstrate that the *APOE‐*ε*4* carrier status is specifically associated with decreased performance on long‐delay recall trials, without effects on immediate recall or short‐delay recall trials.

2. METHODS {#brb3791-sec-0006}
==========

2.1. Study design {#brb3791-sec-0007}
-----------------

The TRACK‐TBI Pilot study is a multicenter prospective observational study conducted at three Level I Trauma Centers in the U.S.---San Francisco General Hospital (SFGH), University of Pittsburgh Medical Center (UPMC), and University Medical Center Brackenridge (UMCB) in Austin, Texas---using the National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke (NINDS) TBI Common Data Elements (CDEs) (Yue et al., [2013](#brb3791-bib-0091){ref-type="ref"}; Maas et al., [2010](#brb3791-bib-0053){ref-type="ref"}; Duhaime et al., [2010](#brb3791-bib-0022){ref-type="ref"}; Manley et al., [2010](#brb3791-bib-0055){ref-type="ref"}; Wilde et al., [2010](#brb3791-bib-0089){ref-type="ref"}). Inclusion criteria for TRACK‐TBI Pilot were external force trauma to the head presenting to Level I trauma center, and clinically indicated head CT scan within 24 hr of injury. Exclusion criteria were pregnancy, comorbid life‐threatening disease, incarceration, psychiatric hold, and non‐English speaking due to limitations in participation with outcome assessments.

As the goal of the current analysis was to investigate the association between the *APOE‐*ε*4* allele and 6‐month verbal memory outcome after mTBI, uncomplicated by massive intracranial trauma \[e.g., CT evidence of mixed density lesions \>25 mm, midline shift \>5 mm, or evidence of cisternal compression (Marshall et al., [1992](#brb3791-bib-0056){ref-type="ref"})\] or polytrauma, patients were included if ≥18 years of age, with GCS score of 13--15 at ED admission per current definition of mTBI (Teasdale & Jennett, [1974](#brb3791-bib-0083){ref-type="ref"}; ), Marshall CT Score 1--2 (Marshall et al., [1992](#brb3791-bib-0056){ref-type="ref"}), no acute neurosurgical intervention, and no extracranial injuries greater than "mild" (Abbreviated Injury Scale \[AIS\] score \>1 in any extracranial body region). To preserve the integrity of cognitive outcomes analysis, patients with a baseline history or diagnosis of central nervous system (CNS) tumor, cerebrovascular accident (CVA), schizophrenia, bipolar disorder, learning disability, and/or developmental delay were excluded from analysis.

Eligible patients were enrolled through convenience sampling at all three sites. Procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. Institutional Review Board (IRB) approval was obtained at all participating sites. Informed consent was obtained for all patients prior to enrollment in the study. For patients unable to provide consent due to their injury, consent was obtained from their legally authorized representative (LAR). Patients were then re‐consented, if cognitively able, at later inpatient and/or outpatient follow‐up assessments for continued participation in the study.

2.2. Biospecimen acquisition and genotyping {#brb3791-sec-0008}
-------------------------------------------

Specimen acquisition was performed as previously described (Yue et al., [2013](#brb3791-bib-0091){ref-type="ref"}). In brief, blood samples were collected via peripheral venipuncture or existing peripheral venous or arterial indwelling catheters within 24 hr of injury for DNA genotyping. Samples were collected in BD Vacutainer K~2~‐EDTA vacutainer tubes, then aliquoted and frozen in cryotubes at −80°C within 1 hr of collection in accordance with recommendations from the NIH NINDS CDE Biomarkers Working Group (Manley et al., [2010](#brb3791-bib-0055){ref-type="ref"}). DNA was extracted from isolated leukocytes using the Wizard^®^ Genomic DNA Purification Kit as described by the manufacturer (Promega, Madison, WI). *APOE* (rs7412; rs429358) polymorphisms were genotyped using the TaqMan^®^SNP Genotyping Assay (Applied Biosystems, Carlsbad, CA; rs7412 Assay ID\# C\_\_\_\_904973_10; rs429358 Assay ID\# C\_\_\_3084793_20). *APOE* alleles were determined as ε*2* (rs7412(T)/rs429358(T)), ε*3* (rs7412(C)/rs429358(T), or ε*4* (rs7412(C)/rs429358(C)); no ε*1* cases existed in the dataset. For the purposes of evaluating a potential deleterious effect of the *APOE‐*ε*4* allele, patients with ε*2/*ε*2*, ε*2/*ε*3*, and ε*2/*ε*3* genotypes were grouped as *APOE‐*ε*4(−)*, and ε*3/*ε*4* or ε*4/*ε*4* genotypes were grouped as *APOE‐*ε*4(+)*, similar to previous studies (Teasdale et al., [2005](#brb3791-bib-0084){ref-type="ref"}; Sundström et al., [2007](#brb3791-bib-0080){ref-type="ref"}).

2.3. Outcome measures {#brb3791-sec-0009}
---------------------

The California Verbal Learning Test, Second Edition (CVLT‐II) is a verbal learning and memory task with five learning trials, an interference trial, an immediate recall trial performed with and without cues, and a post‐20 min recall trial performed with and without cues. The CVLT‐II was substituted for the Rey Auditory Verbal Learning Test (RAVLT) listed in the NIH NINDS outcome CDEs due to relevant revisions of the Second Edition and higher consistency on between‐norm sets (Stallings, Boake, & Sherer, [1995](#brb3791-bib-0076){ref-type="ref"}). The CVLT‐II has been used in over 200 published clinical and experimental research studies as a measure of episodic verbal learning and memory (Woods, Delis, Scott, Kramer, & Holdnack, [2006](#brb3791-bib-0090){ref-type="ref"}). It has also been found to be one of the most sensitive tests for detecting residual brain damage in patients with brain trauma, able to differentiate between outcomes following mild versus moderate‐severe TBI (Davis, [2016](#brb3791-bib-0019){ref-type="ref"}; Delis, Kramer, Kaplan, & Ober, [2000](#brb3791-bib-0020){ref-type="ref"}). Researchers have found that the CVLT can also accurately predict functional outcomes at the time of testing, including level of current disability, type of current supervision, and return to work status (Hanks, Jackson, & Crisanti, [2016](#brb3791-bib-0036){ref-type="ref"}).

The CVLT‐II subscales allow for differentiation between encoding, consolidation, and retrieval deficits (Vanderploeg, Crowell, & Curtiss, [2001](#brb3791-bib-0087){ref-type="ref"}). Lower scores on the CVLT‐II Short‐Delay Free Recall (SDFR) indicate retroactive interference, while lower scores on the CVLT‐II Long‐Delay Free Recall (LDFR) score indicate the occurrence of rapid forgetting. Free recall trials reflect the degree to which words on the first list are recalled without assistance. Cued recall trials assist the examinee in two ways: (1) by informing them of the categorical structure of the list; and (2) requiring them to use semantic clustering in recalling the target words. Patients with mild cognitive impairment (MCI) will often demonstrate aberrant responses on cued recall trials. Patients with more severe deficits will typically respond with deficits on both free and cued recall trials.

2.4. Statistical analysis {#brb3791-sec-0010}
-------------------------

Descriptive statistics are presented as means and standard deviations (SD) for continuous variables and as proportions for categorical variables. Group differences in demographics and injury characteristics across *APOE‐*ε*4* genotypes were assessed by Pearson\'s chi‐squared test (*X* ^*2*^) for categorical variables, and analysis of variance (ANOVA) for continuous variables. Fisher\'s Exact Test was used to assess for differences in categorical variables with individual cell counts ≤5. Multivariable linear regression was performed to assess the association between *APOE‐*ε*4* genotype and each of the five CVLT‐II outcome measures. Demographic and injury variables were selected based on recommendations and cited predictive value in large studies and systematic reviews in mTBI to include age in years (scalar), education in years (scalar), sex (male vs. female), race (dichotomized to Caucasian vs. other due to small samples of other races), loss of consciousness (LOC; no vs. yes/unknown), posttraumatic amnesia (PTA; no vs. yes/unknown), and presence of intracranial pathology on initial head computed tomography (CT) scan (Jacobs et al., [2010](#brb3791-bib-0041){ref-type="ref"}; Kashluba, Hanks, Casey, & Millis, [2008](#brb3791-bib-0044){ref-type="ref"}; Van der Naalt, [2001](#brb3791-bib-0086){ref-type="ref"}; Carroll et al., [2004](#brb3791-bib-0014){ref-type="ref"}). A history of seizures has been correlated with decreased verbal memory performance in the neurology literature and hence prior medical history (PMH) of seizures was included to serve as a surrogate for baseline cognitive burden (Blake, Wroe, Breen, & McCarthy, [2000](#brb3791-bib-0012){ref-type="ref"}; Schefft et al., [2008](#brb3791-bib-0074){ref-type="ref"}; Berl et al., [2005](#brb3791-bib-0008){ref-type="ref"}). To prevent overfitting, we adhered to the rule of 10 for multiple regression analysis (predictors=9; *n* = 114) (Howell, [2013](#brb3791-bib-0038){ref-type="ref"}; Green, [1991](#brb3791-bib-0030){ref-type="ref"}; ). To account for attributable variance (*R* ^*2*^), a two‐tiered approach was employed for each multivariable regression model. First, demographic and injury history predictors were entered onto the model for each CVLT‐II outcome measure and *R* ^*2*^ was recorded (Table S1); then, *APOE‐*ε*4* status was entered onto the model, and the new *R* ^*2*^ as well as the *ΔR* ^*2*^ from the model without *APOE‐*ε*4* status was calculated and reported. The multivariable regression mean differences (*B*) and their associated 95% confidence intervals (CI) are reported for each predictor in the regression analyses. When appropriate, the regression means and standard errors (SE) are reported for *APOE‐*ε*4(+)* and *APOE‐*ε*4(−)* cohorts. Significance was assessed at α = 0.05. All analyses were performed using Statistical Package for the Social Sciences (SPSS) version 22 (IBM Corporation, Chicago, IL, USA).

3. RESULTS {#brb3791-sec-0011}
==========

3.1. Demographic and injury characteristics {#brb3791-sec-0012}
-------------------------------------------

In total, 114 patients were included in the current analysis (Table [1](#brb3791-tbl-0001){ref-type="table-wrap"}). The majority were male (67%) and of Caucasian race (73%). Mean age was 42.8 ± 16.2 years, and education level was 14.2 ± 2.9 years. Mechanisms of injury included fall (46%), motor vehicle accident (21%), cyclist/pedestrian struck by vehicle (14%), assault (14%), and struck by/against object (4%). Approximately, 12% of patients reported PMH of seizures, while 23% reported absence of LOC and 40% reported absence of PTA. ED GCS deficit (\<15) occurred in 20% of patients, and 25% of patients showed evidence of acute intracranial pathology on initial head CT. *APOE* genotypes were distributed as follows: ε*2/*ε*3 n* = 12 (11%), ε*3/*ε*3 n* = 67 (59%), ε*3/*ε*4 n* = 29 (25%), ε*2/*ε*4 n* = 3 (3%), and ε*4/*ε*4 n* = 3 (3%). Breakdown by ethnicities were: Caucasian: ε2/ε2 = 11, ε3/ε3 = 47, ε3/ε4 = 22, ε2/ε4 = 1, ε4/ε4 = 2; African‐American/African: ε2/ε4 = 2, ε3/ε3 = 7, ε3/ε4 = 6, ε4/ε4 = 1; other races: ε2/ε3 = 1, ε3/ε3 = 13, ε3/ε4 = 1. Overall, 31% of patients were *APOE‐*ε*4(+)*. *APOE* distribution conformed to Hardy--Weinberg equilibrium (allelic frequencies: ε*2 *=* *0.0658, ε*3 *=* *0.7675, ε*4 *=* *0.1667; χ^2^ =0.554, df=5, *p *=* *.990).

###### 

Demographic and clinical information of included patients with mild traumatic brain injury

  Variable                   Overall (*N* = 114)   *APOE* ε*4(−)* (*N* = 79)   *APOE* ε*4(+)* (*N* = 35)   Sig. (*p*)
  -------------------------- --------------------- --------------------------- --------------------------- ------------
  Age (years)                                                                                              
  Mean ± *SD*                42.8 ± 16.2           39.7 ± 16.5                 49.6 ± 13.6                 .002
  Gender                                                                                                   
  Male                       76 (67%)              49 (62%)                    27 (77%)                    .114
  Female                     38 (33%)              30 (38%)                    8 (23%)                     
  Race                                                                                                     
  Caucasian                  83 (73%)              58 (70%)                    25 (30%)                    .012
  African‐American/African   16 (14%)              7 (44%)                     9 (56%)                     
  Other races                15 (13%)              14 (93%)                    1 (7%)                      
  PMH Seizures                                                                                             
  No                         100 (88%)             70 (89%)                    30 (86%)                    .664
  Yes                        14 (12%)              9 (11%)                     5 (14%)                     
  Education (years)                                                                                        
  Mean ± *SD*                14.2 ± 2.9            14.3 ± 3.1                  13.7 ± 2.1                  .280
  Mechanism of injury                                                                                      
  Motor vehicle accident     24 (21%)              17 (22%)                    7 (20%)                     .910
  Cyclist/pedestrian hit     16 (14%)              11 (14%)                    5 (14%)                     
  Fall                       53 (47%)              38 (48%)                    15 (43%)                    
  Assault                    16 (14%)              10 (13%)                    6 (17%)                     
  Struck by/against object   5 (4%)                3 (4%)                      2 (6%)                      
  Loss of consciousness                                                                                    
  No                         26 (23%)              19 (24%)                    7 (20%)                     .634
  Yes/unknown                88 (77%)              60 (76%)                    28 (80%)                    
  Posttraumatic amnesia                                                                                    
  No                         46 (40%)              30 (38%)                    16 (46%)                    .437
  Yes/unknown                68 (60%)              49 (62%)                    19 (54%)                    
  ED arrival GCS                                                                                           
  13--14                     23 (20%)              16 (20%)                    7 (20%)                     .975
  15                         91 (80%)              63 (80%)                    28 (80%)                    
  CT pathology                                                                                             
  Absent                     85 (75%)              58 (73%)                    27 (77%)                    .674
  Present                    29 (25%)              21 (27%)                    8 (23%)                     

Race distributions are reported as row percentages. All other distributions reported as column percentages. The race subgroup "Other races" was combined due to individual small sample sizes of Asian \[*N* = 6; ε*4(−) *= 5, ε*4(+) = *1\], American Indian/Alaskan Native \[*N* = 1; ε*4(−) *= 1\], Hawaiian/Pacific Islander \[*N* = 2; ε*4(−) *= 2\], and more than one race \[*N* = 6; ε*4(−) *= 6\]. ED Arrival GCS was combined due to *N* = 1 for GCS 13 in both *APOE* groups.

*APOE*, apolipoprotein E; CI, confidence interval; ED, emergency department; GCS, Glasgow Coma Scale; PMH, prior medical history; *SD*, standard deviation.
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Demographic and injury characteristics by *APOE‐*ε*4* carrier status are shown in Table [1](#brb3791-tbl-0001){ref-type="table-wrap"}. Notably, *ApoE‐*ε*4(+)* patients were older (49.6 vs. 39.7 years, *p *=* *.002). *APOE‐*ε*4* carrier status differed across races, with African‐American/African patients showing the highest incidence, followed by Caucasians (*p *=* *.012); the higher prevalence of the ε*4* allele in African‐American/African patients, and of the ε*3* allele in Caucasians, is consistent with prior epidemiological reports (Farrer et al., [1997](#brb3791-bib-0025){ref-type="ref"}; Kern et al., [2015](#brb3791-bib-0047){ref-type="ref"}). No other demographic or injury history differences were observed by *APOE‐*ε*4* carrier status.

3.2. *APOE‐*ε*4*(+) is not associated with immediate recall or short‐delay recall at 6 months postinjury {#brb3791-sec-0013}
--------------------------------------------------------------------------------------------------------

For IRT, no significant differences were observed by *APOE‐*ε*4* status (*p *=* *.190). Increasing age was associated with decreasing recall (per‐year *B = *−0.28, 95% CI \[−0.40, −0.16\]; *p *\<* *.001). Increasing education was associated with improved recall (per‐year *B = *0.89 \[0.26, 1.53\]; *p *=* *.006). Caucasian race was associated with a 5.42‐point increase (\[1.33, 9.50\], *p *=* *.010) compared to other races. PTA+ patients were associated with a 5.15‐point decrease (\[−9.01, −1.19\], *p *=* *.011). Patients with intracranial CT pathology showed a mean decrease of 8.49‐points (\[−12.64, −4.34\], *p *\<* *.001) (Table [2](#brb3791-tbl-0002){ref-type="table-wrap"}). The *ΔR* ^*2*^ from adding *APOE‐*ε*4* status was +0.010.

###### 

Multivariable regression of *APOE‐*ε*4* status and 6‐month verbal memory subscales

  Variable                                                            *B* \[95% CI\]            Sig. (*p*)
  ------------------------------------------------------------------- ------------------------- ------------
  Immediate Recall Trials 1--5 (*R* ^2^ = 0.405; Δ*R* ^2^ = +0.010)                             
  *APOE‐*ε*4(+)*                                                      −2.69 \[−6.72, 1.36\]     .190
  Age (per‐year)                                                      −0.28 \[−0.40, −0.16\]    \<.001
  Education (per‐year)                                                0.89 \[0.26, 1.53\]       .006
  Sex (male)                                                          −0.28 \[−4.15, 3.59\]     .886
  Race (Caucasian)                                                    5.42 \[1.33, 9.50\]       .010
  PMH Seizures (yes)                                                  −4.13 \[−9.53, 1.26\]     .132
  LOC (yes/unknown)                                                   1.07 \[−3.48, 5.62\]      .641
  PTA (yes/unknown)                                                   −5.15 \[−9.10, −1.19\]    .011
  CT Pathology (yes)                                                  −8.49 \[−12.64, −4.34\]   \<.001
  Short‐Delay Free Recall (*R* ^2^ = 0.356; Δ*R* ^2^ = +0.012)                                  
  *APOE‐*ε*4(+)*                                                      −0.99 \[−2.27, 0.29\]     .129
  Age (per‐year)                                                      −0.08 \[−0.12, −0.04\]    \<.001
  Education (per‐year)                                                0.23 \[0.03, 0.44\]       .023
  Sex (male)                                                          0.01 \[−1.21, 1.24\]      .985
  Race (Caucasian)                                                    1.38 \[0.08, 2.68\]       .037
  PMH Seizures (yes)                                                  −1.32 \[−3.03, 0.39\]     .129
  LOC (yes/unknown)                                                   0.55 \[−0.89, 1.99\]      .451
  PTA (yes/unknown)                                                   −0.99 \[−2.24, 0.29\]     .122
  CT Pathology (yes)                                                  −2.50 \[−3.81, −1.18\]    \<.001
  Short‐Delay Cued Recall (*R* ^2^ = 0.380; Δ*R* ^2^ = +0.023)                                  
  *APOE‐*ε*4(+)*                                                      −1.02 \[−2.05, 0.00\]     .050
  Age (per‐year)                                                      −0.07 \[−0.10, −0.04\]    \<.001
  Education (per‐year)                                                0.18 \[0.02, 0.34\]       .029
  Sex (male)                                                          0.50 \[−0.48, 1.48\]      .310
  Race (Caucasian)                                                    1.15 \[0.12, 2.19\]       .029
  PMH Seizures (yes)                                                  −1.44 \[−2.81, −0.08\]    .038
  LOC (yes/unknown)                                                   0.27 \[−0.88, 1.42\]      .644
  PTA (yes/unknown)                                                   −1.03 \[−2.03, −0.03\]    .043
  CT Pathology (yes)                                                  −1.85 \[−2.90, −0.85\]    \<.001
  Long‐Delay Free Recall (*R* ^2^ = 0.415; Δ*R* ^2^ = +0.022)                                   
  *APOE‐*ε*4(+)*                                                      −1.17 \[−2.33, −0.01\]    .049
  Age (per‐year)                                                      −0.08 \[−0.11, −0.04\]    \<.001
  Education (per‐year)                                                0.22 \[0.03, 0.42\]       .010
  Sex (male)                                                          0.58 \[−0.53, 1.69\]      .304
  Race (Caucasian)                                                    1.69 \[0.58, 2.87\]       .005
  PMH seizures (yes)                                                  −1.49 \[−3.05, 0.06\]     .059
  LOC (yes/unknown)                                                   0.45 \[−0.86, 1.76\]      .499
  PTA (yes/unknown)                                                   −1.28 \[−2.42, −0.14\]    .028
  CT pathology (yes)                                                  −2.61 \[−3.80, −1.42\]    \<.001
  Long‐Delay Cued Recall (*R* ^2^ = 0.408; Δ*R* ^2^ = +0.050)                                   
  *APOE‐*ε*4(+)*                                                      −1.58 \[−2.63, −0.52\]    .004
  Age (per‐year)                                                      −0.06 \[−0.09, −0.03\]    \<.001
  Education (per‐year)                                                0.16 \[−0.01, 0.32\]      .062
  Sex (male)                                                          0.44 \[−0.57, 1.45\]      .386
  Race (Caucasian)                                                    1.14 \[0.07, 2.20\]       .038
  PMH Seizures (yes)                                                  −0.96 \[−2.38, 0.45\]     .180
  LOC (yes/unknown)                                                   0.35 \[−0.83, 1.54\]      .556
  PTA (yes/unknown)                                                   −0.69 \[−1.73, 0.34\]     .186
  CT Pathology (yes)                                                  −2.60 \[−3.69, −1.52\]    \<.001

Tier 2 of the hierarchical multivariable linear regression with the response variables being five verbal memory subscales of the California Verbal Learning Test, Second Edition (CVLT‐II). Mean increase or decrease (*B)* and associated 95% confidence intervals \[95% CI\] are reported for each predictor.

*APOE*, apolipoprotein E; CT, computed tomography; LOC, loss of consciousness; PMH, prior medical history; PTA, posttraumatic amnesia.

John Wiley & Sons, Ltd

For SDFR, no significant differences were observed by *APOE‐*ε*4* status (*p *=* *.129) (Figure [2](#brb3791-fig-0002){ref-type="fig"}). Age was associated with decreased recall (per‐year *B = *−0.08 \[−0.12, −0.04\]; *p *\<* *.001). Education was associated with improved recall (per‐year *B = *0.23 \[0.03, 0.44\]; *p *=* *.023). Caucasian race (*B *=* *1.38 \[0.08, 2.68\], *p *=* *.037) and intracranial CT pathology (*B *=* *−2.50 \[−3.81, −1.18\], *p *\<* *.001) remained predictors. The *ΔR* ^*2*^ from adding *APOE‐*ε*4* status was +0.012.

![Six‐month verbal memory performance, by *APOE‐*ε*4* carrier status. Performance on four CVLT‐II subscales (SDFR, Short‐Delay Cued Recall (SDCR), Long‐Delay Free Recall (LDFR), LDCR) at 6 months postinjury are shown for 114 mTBI patients, by *APOE‐*ε*4* carrier status. Raw scores for each CVLT‐II subscale are controlled for age, education, sex, race, prior medical history (PMH) seizures, loss of consciousness, posttraumatic amnesia, and acute intracranial pathology on head CT scan. Multivariable regression means and 95% confidence intervals are shown for *APOE‐*ε*4* groups. *APOE‐*ε*4(−)*, blue; *APOE‐*ε*4(+)*, red. *APOE*, apolipoprotein E; CT, computed tomography; CVLT‐II, California Verbal Learning Test, Second Edition; LDCR, Long‐Delay Cued Recall; LDFR, Long‐Delay Free Recall; mTBI, mild traumatic brain injury; PMH, prior medical history; SDCR, Short‐Delay Cued Recall; SDFR, Short‐Delay Free Recall](BRB3-7-e00791-g002){#brb3791-fig-0002}

For Short‐Delay Cued Recall (SDCR), *APOE‐*ε*4(+)* patients showed a marginal decrease in performance (*B *=* *−1.02 \[−2.05, 0.00\], *p *=* *.050) compared with their *APOE‐*ε*4(−)* counterparts (Figure [2](#brb3791-fig-0002){ref-type="fig"}). Age was associated with decreased recall (per‐year *B = *−0.07 \[−0.10, −0.04\]; *p *\<* *.001). Education was associated with improved recall (per‐year *B = *0.18 \[0.02, 0.34\]; *p *=* *.029). Caucasian race remained protective (*B *=* *1.15 \[0.12, 2.19), *p *=* *.029), while CT pathology was deleterious (*B *=* *−1.85 \[−2.90, −0.85\], *p *\<* *.001). Having experienced PTA (*B *=* *−1.03 \[−2.03, −0.03\], *p *=* *.043) and PMH of seizures (*B *=* *−1.44 \[−2.81, −0.08\], *p *=* *.038) emerged as predictors. The Δ*R* ^*2*^ from adding *APOE‐*ε*4* status was +0.023.

3.3. *APOE‐*ε*4(+)* is associated with impaired long‐delay recall at 6 months postinjury {#brb3791-sec-0014}
----------------------------------------------------------------------------------------

For LDFR, *APOE‐*ε*4(+)* patients showed a significant decrease in verbal memory function (*B *=* *−1.17 \[−2.33, −0.01\], *p *=* *.049) compared with *APOE‐*ε*4(−)* (Figure [2](#brb3791-fig-0002){ref-type="fig"}). Age was associated with decreased recall (per‐year *B = *−0.08 \[−0.11, −0.04\]; *p *\<* *.001). Education was associated with improved recall (per‐year *B = *0.22 \[0.03, 0.42\]; *p *=* *.010). Caucasian race remained protective (*B *=* *1.69 \[0.58, 1.69\], *p *=* *.005), while PTA+ (*B *=* *−1.28 \[−2.42, −0.14\], *p *=* *.028) and CT pathology remained deleterious (*B *=* *−2.61 \[−3.80, −1.42\], *p *\<* *.001). The *ΔR* ^*2*^ from adding *APOE‐*ε*4* status was +0.022.

For Long‐Delay Cued Recall (LDCR), *APOE‐*ε*4(+)* patients showed a similar decrease in recall ability (*B *=* *−1.58 \[−2.63, −0.52\], *p *=* *.004) compared with *APOE‐*ε*4(−)* (Figure [2](#brb3791-fig-0002){ref-type="fig"}). Age was associated with decreased recall (per‐year *B = *−0.06 \[−0.09, −0.03\]; *p *\<* *.001). Education was associated with marginally improved recall (per‐year *B = *0.16 \[−0.01, 0.32\]; *p *=* *.062). Caucasian race remained protective (*B *=* *1.14 \[0.07, 2.20\], *p *=* *.038), while CT pathology (*B *=* *−2.60 \[−3.69, −1.52\], *p *\<* *.001) continued to be deleterious to verbal memory function. The Δ*R* ^*2*^ from adding *APOE‐*ε*4* status was +0.050.

4. DISCUSSION {#brb3791-sec-0015}
=============

In a prospective study examining the association between *APOE‐*ε*4* and verbal memory deficits after isolated mTBI, we find that *APOE‐*ε*4(+)* is independently associated with impaired long‐delay free and cued recall at 6 months postinjury when compared with *APOE‐*ε*4(−)* patients. We also demonstrate that intracranial CT pathology remains a strong independent driver of decreased 6‐month verbal memory performance after mTBI.

4.1. APOE expression, distribution, and function {#brb3791-sec-0016}
------------------------------------------------

ApoE is synthesized primarily by astrocytes, with some neuronal expression (Aoki et al., [2003](#brb3791-bib-0004){ref-type="ref"}; Orihara & Nakasono, [2002](#brb3791-bib-0067){ref-type="ref"}; \] and used for cell membrane repair, growth of neurites, and synaptogenesis. ApoE facilitates neuronal repair processes in deep brain structures including the hippocampus, entorhinal complex, parahippocampal gyrus, and basal ganglia (Crawford et al., [2002](#brb3791-bib-0018){ref-type="ref"}), areas essential to memory consolidation processes which are consistently damaged following TBI (Bigler, [1987](#brb3791-bib-0009){ref-type="ref"}; Bigler, Anderson, & Blatter, [2002](#brb3791-bib-0010){ref-type="ref"}; Graham, Lawrence, Adams, Doyle, & McLellan,[1988](#brb3791-bib-0029){ref-type="ref"}). Studies measuring cerebral blood flow (CBF) demonstrated that *APOE‐*ε*4(+)* patients showed negative associations between verbal memory and decreased CBF in the medial frontal cortex, insula, and basal ganglia (Zlatar et al., [2016](#brb3791-bib-0092){ref-type="ref"}). Nathoo et al. noted that *APOE‐*ε*4* carriers show a greater propensity for developing age‐related cognitive impairment, a decrease in the synapse‐neuron ratio, and an increased susceptibility to exogenous neurotoxins and hippocampal atrophy independent of head trauma (Nathoo, Chetry, van Dellen, Connolly, & Naidoo, [2003](#brb3791-bib-0064){ref-type="ref"}).

Increasing evidence suggests that ApoE‐ε4 can impede recovery via several mechanisms, including less efficient lipid transport, more beta‐amyloid accumulation, and predisposition to cerebral amyloid angiopathy (Kay et al., [2003](#brb3791-bib-0046){ref-type="ref"}; Nicoll, Roberts, & Graham, [1995](#brb3791-bib-0065){ref-type="ref"}; Greenberg, Rebeck, Vonsattel, Gomez‐Isla, & Hyman, [1995](#brb3791-bib-0031){ref-type="ref"}), increased inflammatory response, and impaired cerebral perfusion (Grocott et al., [2001](#brb3791-bib-0032){ref-type="ref"}; Kerr, Kraus, Marion, & Kamboh, [1999](#brb3791-bib-0048){ref-type="ref"}), as well as compromised blood--brain barrier and marked cerebral edema (Methia et al., [2001](#brb3791-bib-0059){ref-type="ref"}; Lynch et al., [2002](#brb3791-bib-0052){ref-type="ref"}). Previous work from the veteran population have shown that *APOE‐*ε*4(+)* patients experienced more difficulty with memory compared to those who were *APOE‐*ε*4(−)* following equally severe TBI, as measured on the CVLT‐II verbal memory and fluency measures at 6 months (Crawford et al., [2002](#brb3791-bib-0018){ref-type="ref"}). Similarly, Anderson et al. ([2009](#brb3791-bib-0003){ref-type="ref"})showed poorer verbal intellectual and verbal memory skills in those who were *APOE‐*ε*4(+)*, although the differences were not statistically significant after adjusting for multiple comparisons. Of note, ApoE‐ε4 has been associated with verbal memory deficits in mTBI but not with the other aspects of executive function. Significant hippocampal atrophy and temporal horn enlargement have a tendency to occur after TBI, and between 2--7 months postinjury, temporal horn volumes correlated with measured intelligence quotients, while hippocampal volume correlated with verbal memory function (Bigler et al., [2002](#brb3791-bib-0010){ref-type="ref"}). Findings in APOE‐knockout mice after TBI demonstrated marked learning deficits associated with neuronal death specifically in the hippocampus. Thus, ApoE is proposed to play a key role in the neuronal repair of the hippocampus and the surrounding regions through isoform‐dependent clearance of beta‐amyloid depositions after trauma (Fagan & Holtzman, [2000](#brb3791-bib-0024){ref-type="ref"}).

4.2. *APOE‐*ε*4(+)* associates with impaired long‐term verbal memory following mTBI {#brb3791-sec-0017}
-----------------------------------------------------------------------------------

The CVLT‐II tests encoding, consolidation, and retrieval. The long‐delay recall subtests assess forgetting rates over longer intervals and provide a score of retention in the absence of retroactive interference (Delis et al., [2000](#brb3791-bib-0020){ref-type="ref"}). Encoding measures the relative rate of learning. Consolidation is a postencoding process that involves maintenance, elaboration, and storage of new information in long‐term memory (LTM). Evidence in the moderate and severe TBI literature has yielded mixed results---Vanderploeg et al. ([2001](#brb3791-bib-0087){ref-type="ref"}) report no difference in encoding did not differ between TBI and controls on SDFR and SDCR, while Noe, Ferri, Colomer, Moliner, and Chirivella ([2010](#brb3791-bib-0066){ref-type="ref"}) found *APOE* genotype to be associated with the trajectory of cognitive recovery but not in memory rehabilitation. In concussed athletes, *APOE‐*ε*4(+)* patients demonstrated greater neurocognitive variability compared to noncarriers (Merritt et al., [2017](#brb3791-bib-0058){ref-type="ref"}), and in mild‐to‐moderate TBI patients, Lieberman reported nonsignificant decreases in performance across a range of neuropsychological tests for *APOE‐*ε*4(+)* patients (Liberman et al., [2002](#brb3791-bib-0051){ref-type="ref"}). Similarly, in a small study of 34 patients following mTBI, *APOE‐*ε*4(+)* was associated with decreased within‐person postinjury performance on three of nine neuropsychological tests (Sundstrom et al., [2004](#brb3791-bib-0079){ref-type="ref"}). Interestingly and importantly we find that, in mTBI patients, subtests of encoding (IRT, SDFR, SDCR) are unaffected or marginally affected by *APOE‐*ε*4(+)* status, while subtests of consolidation are worsened by *APOE‐*ε*4(+)* status. Hence, we extend the findings that information not properly consolidated will rapidly decay from LTM, thus becoming poorly recognized on LDFR and LDCR (Vanderploeg et al., [2001](#brb3791-bib-0087){ref-type="ref"}). While the *R* ^*2*^ values for the regression models are relatively low, they are reasonable for human studies; the 2.2%--5.0% increase in *R* ^*2*^ from the addition of *APOE‐*ε*4* status for LDFR and LDCR, while small, is in line with expectations in a multifactorial model consisting of other validated predictors for mTBI outcome, and is deserving of attention considering it is from a single gene, but should not be overinterpreted. The value, and equipoise, of evaluating *APOE* as a locus of susceptibility and a target for intervention following mTBI remains to be determined in future prospective studies of larger scale and rigorous study design.

Padgett and colleagues describe in a literature review that the relationship between *APOE* and cognitive function following TBI is complex and requires a nuance‐based approach---which can be partially elucidated through analysis of specific deficits in appropriate TBI subpopulations (e.g., mTBI vs. moderate/severe‐TBI; isolated TBI vs. polytrauma) (Padgett et al., [2016](#brb3791-bib-0068){ref-type="ref"}). Following mTBI, episodic verbal memory deficiencies are greatest between complicated mTBI and healthy controls (Tayim, Flashman, Wright, Roth, & McAllister, [2016](#brb3791-bib-0082){ref-type="ref"}). Our analysis replicates this phenomenon, as CT pathology was the driver of decreased cognitive performance following mTBI, with greater deleterious associations with consolidation and retrieval rather than encoding. This supports the idea that following ischemia and neuronal damage, the reduced antioxidant and biological activity of the ε*4* allele may exacerbate vascular endothelial injury (Bell et al., [2012](#brb3791-bib-0007){ref-type="ref"}; Halliday et al., [2016](#brb3791-bib-0034){ref-type="ref"}) and lead to cognitive deficits (Friedman et al., [1999](#brb3791-bib-0026){ref-type="ref"}). Similar results have been described in AD patients with left temporal and/or hippocampal damage, where a subtle decline in episodic memory occurs prior to the emergence of full dementia. The presence of the *APOE‐*ε*4* allele increases deposition of beta‐amyloid plaques, and has been shown to independently contribute to the prediction of conversion dementia when measured by tests of episodic memory such as the CVLT‐II (Lange et al., [2002](#brb3791-bib-0049){ref-type="ref"}).

4.3. *APOE‐*ε*4(+)*, demographics, and outcome {#brb3791-sec-0018}
----------------------------------------------

Age and education effects on the CVLT‐II subscales have been previously described (Delis et al., [2000](#brb3791-bib-0020){ref-type="ref"}). There is a known association between increasing age and decreasing performance (Delis et al., [2000](#brb3791-bib-0020){ref-type="ref"}; Wiens, Tindall, & Crossen, [1994](#brb3791-bib-0088){ref-type="ref"}; Paolo, Troster, & Ryan, [1997](#brb3791-bib-0070){ref-type="ref"}) and hence the CVLT‐II manual recommends controlling for age when analyzing CVLT‐II performance (Delis et al., [2000](#brb3791-bib-0020){ref-type="ref"}). In our sample, age was a statistically significant independent predictor of poorer verbal memory performance across all CVLT‐II subscales, which may be due to a combination of normal cerebral aging processes leading to slower verbal memory processing---a finding consistent with prior reports in mTBI (Jacobs et al., [2010](#brb3791-bib-0041){ref-type="ref"}). It should be noted that in our sample, *APOE‐*ε*4(+)* patients were on average 10 years older than ε*4(−)* patients, which may further compound their decreased verbal memory performance of the ε*4*‐carriers. This also constitutes a limitation of the current analysis, and future studies should incorporate ε*4(+)* and ε*4(−)* cohorts matched by age (e.g., *APOE‐*ε*4(+)* individuals vs. *APOE‐*ε*4(−)* "controls") in the study design. Education years was also an independent predictor of verbal memory outcomes following mTBI in the current analysis. Previous reports regarding education effects on the CVLT‐II are more unclear; Paolo et al. ([1997](#brb3791-bib-0070){ref-type="ref"}) report that education affects only 14% of CVLT‐II indices, and Wiens et al. ([1994](#brb3791-bib-0088){ref-type="ref"}) did not find a consistent contribution of education to CVLT‐II. However, education is a known predictor of protracted return to work following mTBI (Stulemeijer, van der Werf, Borm, & Vos, [2007](#brb3791-bib-0078){ref-type="ref"}), in part as a proxy for baseline reading and literacy capabilities (Dotson, Kitner‐Triolo, Evans, & Zonderman, [2009](#brb3791-bib-0021){ref-type="ref"}; Albert & Teresi, [1999](#brb3791-bib-0001){ref-type="ref"}; ), as well as postinjury coping/resilience, socioeconomic status, and social support.

The relationship between race and CVLT‐II has been previously described (Delis et al., [2000](#brb3791-bib-0020){ref-type="ref"}; Nathoo et al., [2003](#brb3791-bib-0064){ref-type="ref"}). In our study, race was associated with CVLT performance after injury. The reason for this is unclear, and may be related to a variety of factors. The ε*4* allele is more common in individuals of African‐American/African descent compared with Caucasians (Farrer et al.,[1997](#brb3791-bib-0025){ref-type="ref"}; Kern et al., [2015](#brb3791-bib-0047){ref-type="ref"}), and evidence suggests that ε*4* allele effects are weaker in the former (Kaup et al., [2015](#brb3791-bib-0045){ref-type="ref"}). Caucasian patients are more likely to have better access to healthcare and rehabilitation following TBI (Gasquoine, [2009](#brb3791-bib-0027){ref-type="ref"}; ). Further, recent reports show that African‐American and Hispanic patients are less likely to be placed in acute rehabilitation (Shafi et al., [2007](#brb3791-bib-0075){ref-type="ref"}). Hence, racial differences in access to care, and the quality of care received, may additionally influence CVLT performance following mTBI. *APOE‐*ε*4* has also been implicated in differential predilections for developing cerebrovascular disease across ethnicities (Gavett, John, Gurnani, Bussell, & Saurman, [2015](#brb3791-bib-0028){ref-type="ref"}). These represent important future directions for the study of *APOE* in mTBI.

4.4. Limitations {#brb3791-sec-0019}
----------------

This study has a relatively small population (*n* = 114), which may have impacted the true strength of association between *APOE‐*ε*4(+)* and short‐delay recall trials, as well as limiting the applicability of our study to all mTBI patients. Due to our small sample size, we were unable to control for additional confounders without risk of overfitting the regression model, which further limits the generalizability of our results. The deleterious impacts on verbal memory attributable to *APOE* were also relatively small, especially in context of positive CT pathology. While there is some evidence that *APOE‐*ε*2* may confer a protective effect on cognitive health (Suri, Heise, Trachtenberg, & Mackaey, [2013](#brb3791-bib-0081){ref-type="ref"}), we were not able to investigate this aside from *APOE‐*ε*4* effects due to small sample size. While we controlled for race using multivariable analysis, we were unable to assess differences attributable to *APOE‐*ε*4(+)* within individual races. *APOE* effects in the context of disparate patterns of cognitive decline by race (Gu et al., [2015](#brb3791-bib-0033){ref-type="ref"}) present an additional confounder that cannot be addressed in detail by this study. Also, as the CVLT‐II was administered in English, patients whose first language is not English may perform with subtle differences. While out of scope of the current analysis, the long‐term associations between *APOE‐*ε*4* and outcomes after mTBI also warrant further investigation; another study in 396 severe TBI patients found no clear differences between ε4‐carriers and noncarriers on neuropsychological test performance at a follow‐up interval of 15--26 years postinjury (Millar, Nicoll, Thornhill, Murray, & Teasdale, [2003](#brb3791-bib-0060){ref-type="ref"}), while a separate study reports poorer cognitive functioning in *APOE‐*ε*4(+)* individuals three decades after TBI (Isoniemi, Tenovuo, Portin, Himanen, & Kairisto, [2006](#brb3791-bib-0040){ref-type="ref"}; ). Finally, as stated previously, the attributable R2 change to *APOE‐*ε*4* status is relatively small in the context of other validated predictors for mTBI outcome, and the value of *APOE* as a target for therapeutic evaluation following mTBI remains to be determined pending future work toward elucidating molecular mechanisms, and defining the criteria for heightened surveillance and/or intervention.

The TRACK‐TBI Pilot study was also limited by the variables of the NIH NINDS TBI CDEs version 1, which did not include the highest level of granularity for certain periinjury measures, for example, scalar duration in minutes and/or hours of LOC and PTA which may have been useful for estimating relative mTBI severity. Additionally, the NIH NINDS TBI CDEs version 1 recommended follow‐up using neurocognitive measures at the single time point of 6 months, which prevents analysis of verbal memory recovery over time. These issues will be better addressed by the larger sample size and multiple postinjury outcomes assessment time points as part of the ongoing 12‐center Transforming Research and Clinical Knowledge in Traumatic Brain Injury study in the U.S. (TRACK‐TBI; <http://tracktbi.ucsf.edu>) and 22‐country Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER‐TBI; <http://www.center-tbi.eu>) study in the European Union (Maas et al., [2015](#brb3791-bib-0054){ref-type="ref"}).

5. CONCLUSIONS {#brb3791-sec-0020}
==============

Presence of the *APOE‐*ε*4* allele is associated with decreased long‐term verbal memory on two subscales of the CVLT‐II independent of demographics, injury history, and intracranial CT pathology, suggesting disruption to consolidation and retrieval processes following mTBI. These results support and extend previous findings between *APOE‐*ε*4* and impaired cognitive function, and preliminarily strengthen the link between long‐term verbal memory deficits after mTBI and the pathophysiology of neurodegenerative disorders. Future prospective studies targeting *APOE‐*ε*4* are needed to validate these findings.
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